151. Antibody-based validation of CNS ion channel drug targets
- Author
-
James S. Trimmer and Kenneth J. Rhodes
- Subjects
Drug ,Physiology ,media_common.quotation_subject ,Context (language use) ,Computational biology ,Biology ,Bioinformatics ,Antibodies ,03 medical and health sciences ,0302 clinical medicine ,Animals ,Humans ,Ion channel ,030304 developmental biology ,media_common ,0303 health sciences ,Epilepsy ,Drug discovery ,Brain ,Immunohistochemistry ,3. Good health ,Potassium Channels, Voltage-Gated ,Drug Design ,Perspective ,biology.protein ,Antibody ,030217 neurology & neurosurgery ,Function (biology) ,Central Nervous System Agents ,Perspectives - Abstract
Target validation and selection are critical early steps in the drug discovery process as they trigger substantial activity and investment to identify potential drug candidates. Antibodies play a crucial role in target selection as they provide powerful tools to explore the distribution and subcellular location of candidate molecules and can also be used to explore function. For studies of ion channel targets, antibodies are indispensable as they allow for direct exploration of the subunit composition of channel complexes in native tissues using biochemical and anatomical methods. This perspective summarizes the application of antibodies to target characterization and validation within the context of a CNS therapeutic discovery program targeting voltage-gated K+ channels. We also discuss a strategy for the development, characterization, and validation of high-quality antibody reagents to support key activities in drug discovery.
- Published
- 2008